IL310010A - Biologically produced nucleic acid for vaccine production - Google Patents

Biologically produced nucleic acid for vaccine production

Info

Publication number
IL310010A
IL310010A IL310010A IL31001024A IL310010A IL 310010 A IL310010 A IL 310010A IL 310010 A IL310010 A IL 310010A IL 31001024 A IL31001024 A IL 31001024A IL 310010 A IL310010 A IL 310010A
Authority
IL
Israel
Prior art keywords
nucleic acids
vaccine production
biologically produced
produced nucleic
biologically
Prior art date
Application number
IL310010A
Other languages
English (en)
Hebrew (he)
Inventor
Enja Tatjana Kipfer
Thomas Klimkait
Christian Mittelholzer
Fabian Otte
Original Assignee
Universit?T Basel
Enja Tatjana Kipfer
Thomas Klimkait
Christian Mittelholzer
Fabian Otte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universit?T Basel, Enja Tatjana Kipfer, Thomas Klimkait, Christian Mittelholzer, Fabian Otte filed Critical Universit?T Basel
Publication of IL310010A publication Critical patent/IL310010A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL310010A 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production IL310010A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21195643 2021-09-09
EP22179777 2022-06-19
PCT/EP2022/075140 WO2023036947A1 (en) 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production

Publications (1)

Publication Number Publication Date
IL310010A true IL310010A (en) 2024-03-01

Family

ID=83558295

Family Applications (1)

Application Number Title Priority Date Filing Date
IL310010A IL310010A (en) 2021-09-09 2022-09-09 Biologically produced nucleic acid for vaccine production

Country Status (9)

Country Link
US (1) US20250188127A1 (https=)
EP (1) EP4398935A1 (https=)
JP (1) JP2024533378A (https=)
KR (1) KR20240055051A (https=)
AU (1) AU2022341555A1 (https=)
CA (1) CA3224963A1 (https=)
IL (1) IL310010A (https=)
MX (1) MX2024002259A (https=)
WO (1) WO2023036947A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543046A (ja) * 2019-07-30 2022-10-07 バーンダリ・インコーポレイテッド ウイルス様粒子ワクチン

Also Published As

Publication number Publication date
JP2024533378A (ja) 2024-09-12
KR20240055051A (ko) 2024-04-26
AU2022341555A1 (en) 2024-01-18
WO2023036947A1 (en) 2023-03-16
EP4398935A1 (en) 2024-07-17
MX2024002259A (es) 2024-03-06
AU2022341555A9 (en) 2024-01-25
CA3224963A1 (en) 2023-03-16
US20250188127A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
IL287468A (en) Nucleic acid constructs and methods for their manufacture
EP3746564A4 (en) METHOD OF NUCLEIC ACID AMPLIFICATION
EP3938379A4 (en) Hiv rna vaccines
IL271342A (en) Nucleic acid-guided nucleases
EP3630130A4 (en) PROCESS FOR GENERATING PERSONALIZED CANCER VACCINES
EP4376883A4 (en) RNA VACCINES
DK3523430T3 (da) Manipulerede nukleinsyremålrettede nukleinsyrer
MA41510A (fr) Procédé de production d'acide acrylique
EP3450569A4 (en) METHOD FOR DNA AMPLIFICATION
EP3470529A4 (en) METHOD FOR ISOTHERMAL NUCLEIC ACID SELF-REINFORCEMENT
EP4159234A4 (en) VACCINE AGAINST SARS-COV-2
EP3508587A4 (en) Dna sequencing method
EP3460058A4 (en) METHOD FOR AMPLIFICATING CYCLIC DNA
DK4259617T3 (da) Substituerede pyrazolpiperidincarboxylsyrer
EP4413144A4 (en) RNA VACCINE LIPID NANOPARTICLES
EP3480183A4 (en) METHOD OF MANUFACTURING (METH) ACRYLIC ACID OR AN ESTER THEREOF
EP3346006A4 (en) METHOD FOR DNA AMPLIFICATION
EP3495491A4 (en) METHOD FOR PRODUCING RECOMBINANT PROTEINS
EP4479095C0 (en) STABILIZED STEALTH LIPO-POLYAMINE ACIDS
EP3940053A4 (en) METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS
EP3524063A4 (en) METHOD FOR PRODUCING NUCLEIC ACID SPICES
EP4166158A4 (en) NUCLEIC ACID LIPID PARTICLE VACCINE
EP3663407A4 (en) METHOD OF NUCLEIC ACID SEQUENCING
EP3381887A4 (en) PROCESS FOR PREPARING ACETIC ACID
IL292839A (en) Process and system for producing an inoculum